Medicare Laboratory Test Reimbursement Shift

Medicare beneficiaries might experience changes in laboratory test reimbursements. The Centers for Medicare & Medicaid Services (CMS) released preliminary 2027 rates for clinical lab services, based on private insurer payment data. This data collection, under the Protecting Access to Medicare Act (PAMA), aligns Medicare payments with market prices.

According to CMS, Medicare has paid 16 percent more for lab services than private insurers. Aligning these rates could save taxpayers roughly $1 billion annually. Dr. Mehmet Oz, CMS Administrator, stated, “Taxpayers and Medicare patients have been paying excessive rates to labs for years…”

The Importance of Lab Testing

Lab testing is integral to modern healthcare. It ranges from routine blood work to advanced diagnostics. Changes in reimbursement levels focus on lab revenues and raise concerns over Medicare’s payment methodology accuracy.

While out-of-pocket costs for most beneficiaries should remain unaffected, lab groups fear cuts might impact patient access to testing, especially in rural areas.

Detailed Insights into Preliminary Rates

CMS shared weighted median private-payor rates for diagnostic tests under the Clinical Laboratory Fee Schedule (CLFS). Categories facing potential reductions include:

Genomic sequencing: -23 percent
Molecular pathology: -22 percent
Microbiology: -19.3 percent
Immunology testing: -19.3 percent

Chemistry testing faces a 16 percent reduction, while proprietary lab tests see a smaller reduction of 2.4 percent. These changes will be phased over the years due to federal limits on reduction rates.

Comments and Concerns

The public commenting period remains open for 30 days before final rates are published. Criticism came from Quest Diagnostics, highlighting flaws in the PAMA reporting system. They urge Congress to pass the RESULTS Act for a stronger laboratory system.

Quest conducted a survey showing 96 percent of voters find diagnostic testing vital for their care. 74 percent believe Congress should act against further payment cuts.

Future Implications

Final payment rates will be released in November after CMS reviews public submissions. Concerns arise about Medicare aligning closer to Medicare Advantage, potentially increasing prior authorizations and coverage denials.

Reimbursement reductions might lead to tradeoffs, impacting beneficiaries’ access to services. The American Clinical Laboratory Association notes nearly 1,200 tests might face the maximum allowable 15 percent cut by 2027.